From Our Thought Leaders

Merck Raises 2026 Guidance After Strong Q2 Performance, Says CEO Kai Beckmann

Merck has reported strong financial results for the second quarter of 2026, driven by sustained growth across its Life Science and Electronics businesses. The company posted organic net sales growth of 4.1% and organic EBITDA pre growth of 9.3%, pr... Read more

07 August, 2026 | Friday | Company results
QIAGEN CEO Thierry Bernard Cites Growth Momentum as Q2 Results Top Expectations

Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline Growth pillars deliver about 5% CER growth, led by Sample... Read more

07 August, 2026 | Friday | Company results
CEO Daniel O’Day Highlights Gilead’s Strong Q2 Growth and Clinical Momentum

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08... Read more

06 August, 2026 | Thursday | Company results
CEO Norman Schwartz Reaffirms Bio-Rad’s 2026 Outlook Despite Life Science Headwinds

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad’s Chairman and Chi... Read more

06 August, 2026 | Thursday | Company results

Bio Finance

Basilea Secures Additional USD 30 Million BARDA Funding for Phase 3 Antifungal Program

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced  that the Biomedical Advanced Research and Develop... Read more

29 July, 2026 | Wednesday | News
Idorsia Secures CHF 250 Million Financing Facility to Strengthen Balance Sheet and Extend Cash Runway

Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Money Facility, maturing in May 2027 Eliminates near‑term debt maturities and strengthens b... Read more

10 June, 2026 | Wednesday | News

Contract Services

AGC Biologics Secures Multi-Year Commercial Manufacturing Agreement for Yokohama Facility

Reached a long-term business cooperation with a large pharmaceutical company to help it promote production licensing and commercial supervision and approval in major markets. Customers choose AGC Biologics Yokohama's new base to promote five com... Read more

30 July, 2026 | Thursday | News
Samsung Biologics Announced CHF 1.46 Billion Tender Offer to Acquire PolyPeptide

  Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approxim... Read more

21 July, 2026 | Tuesday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close